Vitamin Casa Serum Uric Acid Lowering Agent in Hyperuricaemia | [Journal of the College of Physicians and Surgeons Pakistan • 2025]

Author(s):

1. Iqra Siddiqui: Department of Pharmacology and Therapeutics, Shaheed Zulfiqar Ali Bhutto Medical University,Islamabad,Pakistan

2. Moosa Khan: Department of Pharmacology and Therapeutics, Shaheed Zulfiqar Ali Bhutto Medical University,Islamabad,Pakistan

3. Faiza Rehman: Department of Pharmacology and Therapeutics, Shaheed Zulfiqar Ali Bhutto Medical University,Islamabad,Pakistan

4. Maleeha Abbas: Department of Pharmacology and Therapeutics, Shaheed Zulfiqar Ali Bhutto Medical University,Islamabad,Pakistan

5. Shahnawaz Jamali: Department of Pharmacology and Therapeutics, Shaheed Zulfiqar Ali Bhutto Medical University,Islamabad,Pakistan

Abstract:

To assess the impact of Vitamin C supplementation compared to Allopurinol therapy on the modulation of serum uric acid levels in individuals diagnosed with hyperuricaemia. Study Design: A comparative analytical study. Place and Duration of the Study: Department of Pharmacology and Therapeutics, Shaheed Zul qar Ali Bhutto Medical University, in collaboration with the Department of Medicine and Rheumatology, Pakistan Institute of Medical Sciences, Islamabad, Pakistan, from May to December, 2023. Methodology: Eighty-six hyperuricaemic patients were enrolled and segregated equally into two groups. Group 1 received Allopurinol while Group 2 received Allopurinol plus Vitamin C. Serum uric acid levels at days 0, 30, and 60 were monitored for the serum uric acid-lowering e ect of medicines. Frequency and percentages were presented for qualitative variables such as gender and age. An independent t-test was applied to compare the serum uric acid level at di erent intervals between both groups. A p-value equal to or less than <0.05 was considered statistically signi cant. Results: The Allopurinol Group's baseline serum uric acid level was 8.321 ± 0.097 mg/dl, and the baseline value of serum uric acid of Allopurinol plus Vitamin C was 8.547 ± 0.101 mg/dl. At day 60th, the mean serum uric acid level in the Allopurinol group was 7.524 ± 0.097 with p <0.001. In the Vitamin C plus Allopurinol group, the mean serum uric acid level was 6.371± 0.161 with a p-value <0.001. In the Allopurinol plus vitamin C group, the percentage reduction in serum uric acid level was more than 25.44% as compared to the Allopurinol group of 9.51%. Conclusion: Vitamin C used with Allopurinol as an adjunct therapy is a more potent pharmacological strategy for lowering blood uric acid levels in hyperuricaemic patients than alone.

Page(s): 688-692

DOI: 10.29271/jcpsp.2025.06.688

Published: Journal: Journal of the College of Physicians and Surgeons Pakistan, Volume: 35, Issue: 06, Year: 2025

Keywords:

Uric Acid , Vitamin C , allopurinol , Hyperuricaemia

References:

[1] Hussain T,Turab M,Sultana M,Shaikh F,Hasan SS,Khalid S. .2020 .To compare Allopurinol and Febuxostat's e cacy, tolerability, and patient acceptability in Hyperuricemic patients. Turk J Phys Med Rehabil, 6432(4) : 796-806.

[2] Lee HJ,Choi JY,Lee J,Kim D,Min JY,Min KB .2022 .Association between serum uric acid and ±-klotho protein levels in the middle-aged population. Aging (Albany NY), 10(6) : 2537-47.

[3] Liu XX,Wang XX,Cui LL .2021 .Association between Oral Vitamin C supplementation and serum uric acid: A meta-analysis of randomized controlled trials. Complement Ther Med, 102761 : 102761.

[4] Dai C,Wang C,Xia F,Liu Z,Mo Y,Shan X .2021 .Age and gender-speci c reference intervals for uric acid level in children aged 5 14 years in Southeast Zhejiang Province of China: Hyperuricemia in children may need rede nition. Front Pediatr, 560720 : 560720.

[5] Hu Y,Li Q,Min R,Deng Y,Xu Y,Gao L Y .2021 .The association between serum uric acid and diabetic complications in patients with type 2 diabetes mellitus by gender: A crosssectional study. Peer J, 10 : .

[6] Li L,Zhang Y,Zeng C. .2020 .Update on the epidemiology, genetics, and therapeutic options of hyperuricemia. Am J Transl Res, 12(7) : 3167-81.

[7] Ebrahimpour-Koujan S,Saneei P,Larijani B,Esmaillzadeh A .2021 .Consumption of sugar-sweetened beverages and serum uric acid concentrations: A systematic review and metaanalysis. J Hum Nutr Diet, 10(2) : 305-13.

[8] Kimura Y,Tsukui D,Kono H .2021 .Uric acid in in ammation and the pathogenesis of atherosclerosis. Int J Mol Sci, 10(22) : 12394.

[9] Jung SW,Kim SM,Kim YG,Lee SH,Moon JY .2019 .Uric acid and in ammation in kidney disease. Am J Physiol Renal Physiol, 10(6) : F1327-40.

[10] Zhang Y,Chen S,Yuan M,Xu Y,Xu H Y .2022 .Gout and diet: A comprehensive review of mechanisms and management. Nutrients, 10(17) : 3525.

[11] Akari S,Nakamura T,Furusawa K,Miyazaki Y,Kario K. .2022 .The reality of treatment for hyperuricemia and gout in Japan: A historical cohort study using health insurance claims data. J Clin Hypertens (Greenwich), 10(8) : 1068-75.

[12] Ghallab DS,Shawky E,Metwally AM,Celik I,Ibrahim RS,Mohyeldin MM .2022 .Integrated in silico in vitro strategy for the discovery of potential xanthine oxidase inhibitors from Egyptian propolis and their synergistic e ect with allopurinol and febuxostat. RSC Adv, 10(5) : 2843-72.

[13] Benn CL,Dua P,Gurrell R,Loudon P,Pike A,Storer RI .2018 .Physiology of hyperuricemia and urate-lowering treatments. J Rheumatol, 10 : 160.

[14] Marik PE,Vitamin C .2019 .An essential "stress hormone" during sepsis. J Thorac Dis, 12(Suppl 1) : S84-8.

[15] Shen L,Ji HF .2010 .The potential of vitamin C in the prevention and treatment of gout. Nat Rev Rheumatol, 10(6) : 222-c1.

[16] Dean L,Kane M.,Pratt VM,Scott SA,Pirmohamed M,Esquivel B,Kattman BL,Malheiro AJ .2012 .Bethesda (MD): National Center for Bio-technology Information (US. 2020 Dec, 9 : .

[17] Rowe S,Carr AC .2008 .Global vitamin C status and prevalence of de ciency: A cause for concernN?utrients. , 10(7) : .

[18] Brucato A,Cianci F,Carnovale C .2020 .Management of hyperuricaemia in asymptomatic patients: A critical appraisal. Eur J Intern Med, 01 : 8-17.

[19] Turab M,Hasan SS,Zaidi SA,Khalid S,Shaikh F,Zehra D. .49 .The allopurinol and febuxostat in the treatment of hyperuricemic patients and their impact on lipid fractions (cholesterol, LDL, HDL). J Hun Univ Natur Sci, 10(1) : 2974.

[20] Gao X,Curhan G,Forman JP,Ascherio A,Choi HK .2008 .Vitamin C intake and serum uric acid concentration in menJ. Rheumatol, 35(9) : 1853-8.

[21] Kensarah OA,Azzeh FS .2012 .Implementing high vitamin C treatments to decrease blood uric acid levels in hyperuricemic Saudi patients. J Appl Sci, 462 : 462-7.

Citations

Downloads

Views